StreetAlpha.app
Home › Stocks › MIST

Milestone Pharmaceuticals Inc. (MIST)

Healthcare
$0.37
▼ −7.06%
LAST CLOSE · NOV 20

Milestone Pharmaceuticals sells CARDAMYST, a nasal spray for treating a rapid heartbeat condition called PSVT. It last closed at $0.37 on Nov 20, down 7.06% on the day. The next earnings report for MIST is expected around Fri, Mar 19, 2027. For the quarter ended Sep 2026, MIST reported EPS of -$0.18 on revenue of $3.0M. Over its last 8 reports the stock moved an average of 9.6% the session after earnings. Over the last 12 months MIST insiders bought $0 of stock on the open market and sold $1.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is MIST in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MIST.

Key Stats

Last 12 months
Results
Net income
−$97.9M
EPS (diluted)
−$0.74
Free cash flow
−$77.1M
Valuation
Market cap
$46.2M
124.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$144.5M
At Sep 30
Debt
$60.2M
At Sep 30
Shareholder equity
−$6.2M
Shares outstanding
124.5M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$42.9M−$42.9MFY2021FY2022: −$58.4M−$58.4MFY2022FY2023: −$59.7M−$59.7MFY2023FY2024: −$41.5M−$41.5MFY2024FY2025: −$63.1M−$63.1MFY2025

From MIST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 19
Estimated date · Time not announced
Reported EPS
-$0.18
Quarter ended Sep 2026
Year ago EPS
-$0.12
Same quarter last year
Revenue
$3.0M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.19Dec '24Mar 2025: -$0.31Mar '25Jun 2025: -$0.20Jun '25Sep 2025: -$0.12Sep '25Dec 2025: -$0.15Dec '25Mar 2026: -$0.20Mar '26Jun 2026: -$0.21Jun '26Sep 2026: -$0.18Sep '26Latest -$0.18
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Mar 2026: $238,000Mar '26Jun 2026: $559,000Jun '26Sep 2026: $3.0MSep '26Latest $3.0M
How MIST moved after its last 8 reports
Average move the session after a report ±9.6%
Nov 13, 2026Time not announced−20.6%
Aug 12, 2026Time not announced−11.4%
May 13, 2026Time not announced−9.5%
Mar 20, 2026Time not announced−20.0%
Nov 12, 2025Time not announced+1.1%
Aug 12, 2025Time not announced+7.1%
May 14, 2025Time not announced−1.7%
Mar 13, 2025Time not announced+5.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MISTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MIST
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MIST

Technical Analysis

MIST · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 69% below its 20 day and 98% below its 50 day average. It is 243% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $0.36, and the nearest resistance the Pivot at $0.38.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 20.6%/day
Key levels
$3.0652 week high+727.0%
$1.27200 day average+243.2%
$0.95100 day average+156.8%
$0.80Swing high (Nov 4)+116.2%
$0.7350 day average+97.3%
$0.6320 day average+70.3%
$0.39Pivot R1+5.4%
$0.38Pivot+2.7%
$0.37Last close
$0.3652 week low−2.7%
$0.36Pivot S1−2.7%
$0.36Swing low (Nov 16)−2.7%
Indicators
RSI (14)29.83Oversold below 30Oversold
MACD-0.10Below its signal lineBearish
Stochastic11.0Near the bottom of its rangeOversold
ADX (14)33.7Trending down
Williams %R-97.9Oversold below −80, overbought above −20Oversold
CCI (20)-145.8Oversold below −100, overbought above 100Oversold
Rate of change−51.4%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 20.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MIST

What happened before

See how MIST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MIST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MIST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MISTHow many large options trades hit MIST, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

MIST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●27 buying vs 27 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7478−5.1%
In funds' top 10330.0%
Held by funds40.5%40.8%−0.4 pts
New / increased12 / 156 / 22−3.6%
Reduced / sold out14 / 1323 / 13−25.0%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MIST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MIST Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.2M7 sales · 5 insiders
15% of the selling was under pre-arranged trading plans.
2026-01 sold $1.1M2026-04 sold $82KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Apr 16Joseph OlivetoPresident and CEOSale plan36,500$2.26$82K
Jan 26Joseph OlivetoPresident and CEOSale167,577$2.24$375K
Jan 26Lorenz MullerChief Commercial OfficerSale64,746$2.25$146K
Jan 26Amit HasijaCFO & EVP of Corp. DevelopmentSale70,252$2.25$158K
Jan 26David BharuchaChief Medical OfficerSale70,252$2.25$158K
Jan 26Jeffrey Edward NelsonCOOSale70,252$2.25$158K
Every insider buy and sale for MIST over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MIST insider trades →

From SEC Form 4 filings by MIST's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIST is in one of them and how their past MIST trades turned out.

MIST in the AI portfolios
Loading…

MIST News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MIST in an article yet. Here's the latest on the wider market.

MIST in the news

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company based in Montreal, Quebec, Canada, that develops heart medicines. Its main product is CARDAMYST, a nasal spray containing etripamil that patients can use themselves to stop an episode of PSVT, a condition that causes the heart to suddenly beat too fast. The product is sold in the United States through retail pharmacies, and the company is developing etripamil for atrial fibrillation as well. Its customers are patients and the doctors, mainly cardiologists, who prescribe its medicines.

Headquarters
Montreal, Quebec, Canada